Dr. Loken received his M.A. and Ph.D. degrees from The Johns Hopkins University (Biochemistry, Biophysics) followed by a postdoctoral fellowship at Stanford University (Genetics, Immunology). He began working in the field of flow cytometry in 1973 on the first fluorescence activated cell sorter, publishing the first quantitative immunofluorescence paper in 1974. He has been involved with both the technological development of flow cytometers as well as their application to immunology and experimental hematology. He is a charter member of ISAC. He developed the techniques used by everyone in the field to quantify multiple antibodies simultaneously and holds patents on instrument standardization as well as multicolor immunofluorescence.He has applied the understanding of normal hematopoiesis and antigen dysregulation to the diagnosis of hematological abnormalities and monitoring their treatment in a clinical setting. As an Affiliate Scientist at the Fred Hutchinson Cancer Research Center since 1993, Dr. Loken has demonstrated the utility of flow cytometry in the detection of low levels of tumor both pre and post hematopoietic stem cell transplant. These studies have been extended to the diagnosis and prognosis of myelodysplasia. Recent studies have demonstrated the precise regulation of amounts of gene products during hematopoiesis. Phenotypic changes observed in leukemia provide the basis for detection of residual disease based on “Difference from Normal:Myeloid”.